← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › VACCINES › VIRAL VACCINES › Other viral vaccines
dengue virus vaccines
J07BX04
Forms & Strengths
- CYD-TDV: 0.5ml single-dose vial
- Dengvaxia: 0.5ml single-dose syringe
- Takeda TAK-003: 0.5ml single-dose vial
- Sputnik V (Gam-COVID-Vac): 0.5ml single-dose vial
Adult Dosing
- CYD-TDV: 3 doses at 0, 6, and 12 months
- Takeda TAK-003: 2 doses at 0 and 3 months
- Dengvaxia: 3 doses at 0, 6, and 12 months for 9-45 years old
- Sputnik V: 2 doses at 0 and 21 days
Pediatric Dosing
- CYD-TDV: approved for 9-45 years, 3 doses at 0, 6, and 12 months
- Dengvaxia: approved for 9-45 years, 3 doses at 0, 6, and 12 months
- Takeda TAK-003: ongoing clinical trials for <18 years old
- Sputnik V: not approved for <18 years old
Indications
- Prevention of dengue disease caused by dengue virus serotypes 1-4
- Reducing hospitalization due to dengue disease
- Prevention of dengue hemorrhagic fever
Mechanism of Action
- Induces neutralizing antibodies against dengue virus serotypes 1-4
- Stimulates cell-mediated immune response
- Provides immunity against dengue disease through active immunization
Contraindications
- Hypersensitivity to vaccine components
- Severe allergic reaction to previous dengue vaccination
- Immunocompromised individuals, e.g. HIV/AIDS
Adverse Reactions
- Injection site pain, redness, and swelling
- Headache, fatigue, and muscle pain
- Fever, nausea, and vomiting
- Rash, itching, and urticaria
Drug Interactions
- Concomitant use with immunosuppressive therapy may reduce vaccine efficacy
- Caution with concomitant use of antiviral and antibacterial agents
- No interaction studies with other vaccines, use with caution
Curated Content: Needs Vetting Before Put to Clinical Use